Exploring INmune Bio, Inc. (INMB) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease? With 150 institutional owners and shareholders holding a total of 7,183,167 shares, it's worth exploring which institutions are making significant investments and what their motivations might be. In 2024, INmune Bio raised $29.9 million from the sale of common stock and warrants, and while the company reported a net loss of $42.1 million, up from $30 million in 2023, key investors seem to be focusing on the potential of their clinical trials, particularly the Alzheimer's trial set to deliver top-line data in June 2025. Let's delve into the details of who is buying INMB and, more importantly, why they see value in this innovative company.

INmune Bio, Inc. (INMB) Who Invests in INmune Bio, Inc. (INMB) and Why?

Understanding the investor profile of INmune Bio, Inc. (INMB) provides critical insights into the market's perception of the company. Investors are drawn to INmune Bio, Inc. (INMB) for various reasons, influenced by the company's potential in the biotechnology sector, particularly its innovative approach to treating diseases by targeting the innate immune system.

Here's a breakdown of the key investor types, their motivations, and typical investment strategies:

• Key Investor Types:
• Retail Investors: These individual investors often have varying levels of experience and invest based on personal interest or recommendations.
• Institutional Investors: This group includes investment banks, hedge funds, pension funds, and mutual funds, which manage large sums of money on behalf of others.
• Hedge Funds: These funds use more aggressive strategies, including leveraging and short-selling, to maximize returns.

Different investor types exhibit varying behaviors and levels of risk tolerance. For instance, retail investors might be swayed by news headlines and social media trends, while institutional investors conduct thorough research and analysis before making investment decisions.

• Investment Motivations:
• Growth Prospects: Investors are attracted to INmune Bio, Inc. (INMB)'s growth potential, driven by its innovative therapies targeting the innate immune system.
• Market Position: The company's unique approach in addressing unmet medical needs enhances its appeal to investors seeking disruptive technologies.

Investors are keenly observing INmune Bio, Inc. (INMB)’s financial performance and clinical trial outcomes to gauge the viability and potential of its therapeutic candidates. Positive results from clinical trials can significantly boost investor confidence and drive stock prices up.

• Investment Strategies:
• Long-Term Holding: Some investors adopt a long-term holding strategy, banking on the company’s future success and the potential appreciation of its stock over time.
• Short-Term Trading: Other investors engage in short-term trading, capitalizing on the stock's volatility to make quick profits.
• Value Investing: Value investors look for companies they believe are undervalued by the market, with the expectation that the market will eventually recognize their true worth.

Understanding these strategies can help current and potential investors align their investment approach with their financial goals and risk tolerance.

Institutional investors often have a significant impact on INmune Bio, Inc. (INMB)’s stock performance due to the large volumes they trade. Their investment decisions are usually based on in-depth research and analysis, which can influence market sentiment.

Here is a table summarizing key investors of INmune Bio, Inc. (INMB) as of 2024, highlighting their holdings and investment strategies:

For more insights into INmune Bio, Inc. (INMB)'s financial health, you can explore: Breaking Down INmune Bio, Inc. (INMB) Financial Health: Key Insights for Investors

INmune Bio, Inc. (INMB) Institutional Ownership and Major Shareholders of INmune Bio, Inc. (INMB)

Understanding the institutional ownership and major shareholders of INmune Bio, Inc. (INMB) provides valuable insights into the company's stability, investor confidence, and potential strategic direction. Institutional investors, such as mutual funds, hedge funds, and pension funds, often have significant resources and conduct extensive research before investing. Their actions can influence stock price and company policies.

As of the latest available data, several institutional investors hold notable positions in INmune Bio, Inc. (INMB). These firms and their holdings can significantly impact the market perception and stability of the stock. While specific shareholding amounts fluctuate, identifying the top holders offers a glimpse into who has the most influence.

Key aspects to consider regarding institutional ownership include:

• Top Institutional Investors: Identifying the largest institutional investors and their respective shareholdings.
• Changes in Ownership: Monitoring whether these major players have increased or decreased their positions recently.
• Impact on Stock Price and Strategy: Analyzing how institutional investor activity correlates with stock performance and potential shifts in company strategy.

Institutional investors often conduct thorough due diligence before investing in a company. Their investment decisions are typically based on extensive research and analysis, reflecting their confidence in the company's long-term prospects. An increase in institutional ownership can be seen as a positive sign, potentially driving up the stock price due to increased demand.

Conversely, a decrease in institutional ownership might indicate concerns about the company's future performance. Large-scale selling by institutional investors can create downward pressure on the stock price. Therefore, tracking these changes is crucial for understanding market sentiment towards INmune Bio, Inc. (INMB).

Examining the composition of major shareholders can also reveal the alignment of interests between the company's management and its investors. For instance, if a significant portion of shares is held by long-term investors, it suggests a shared vision for the company's growth and stability.

While precise, real-time data on institutional holdings requires continuous monitoring of filings and financial news, keeping an eye on major institutional players provides a macroscopic view of market confidence in INmune Bio, Inc. (INMB). This information is invaluable for current and prospective investors looking to make informed decisions.

For more detailed information on INmune Bio, Inc. (INMB), you might find this resource helpful: INmune Bio, Inc. (INMB): History, Ownership, Mission, How It Works & Makes Money

INmune Bio, Inc. (INMB) Key Investors and Their Impact on INmune Bio, Inc. (INMB)

Understanding the investor profile of INmune Bio, Inc. (INMB) provides valuable insights into the company's stability, growth potential, and market sentiment. Examining who is investing and their recent activities can reveal a great deal about the perceived value and future prospects of the company. Institutional investors, in particular, often have a significant impact due to the size of their holdings and their influence on market trends.

While specific real-time data on all investors and their precise impacts can fluctuate, focusing on publicly available information regarding major stakeholders and their recent moves offers a clear picture. Keep in mind that investment portfolios and strategies can change, so this information reflects a snapshot in time.

Institutional ownership often signals confidence in a company's long-term strategy. Recent activity, such as increases or decreases in holdings, can reflect investor sentiment based on clinical trial results, regulatory milestones, and overall market conditions. For more background information on the company, you can check out: INmune Bio, Inc. (INMB): History, Ownership, Mission, How It Works & Makes Money.

Here are some potential areas to consider when evaluating investor influence and recent moves:

• Major Institutional Holders: Identifying the top institutional investors (e.g., hedge funds, mutual funds, pension funds) and the size of their positions.
• Recent Transactions: Monitoring recent buying or selling activity by these major holders, as reported in SEC filings (Form 4, 13F, etc.).
• Activist Investors: Noting any activist investors who have taken a stake in INmune Bio, Inc. (INMB), as they may push for strategic changes.
• Analyst Ratings: Keeping track of analyst ratings and price targets, which can influence investor sentiment and stock movements.

To illustrate the type of information that is relevant, consider the following example of how to present data (note that the below data is purely illustrative and should be replaced with the most current information):

Disclaimer: Investment information is subject to change and should be independently verified through official sources. This analysis is for informational purposes only and does not constitute financial advice.

INmune Bio, Inc. (INMB) Market Impact and Investor Sentiment

Understanding the investor profile of INmune Bio, Inc. (INMB) involves analyzing investor sentiment, recent market reactions, and analyst perspectives. This provides a comprehensive view of how the market perceives INmune Bio, Inc. (INMB)'s potential and future.

Institutional ownership in INmune Bio, Inc. (INMB) is significant, with 150 institutional owners and shareholders filing 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,183,167 shares. Major shareholders include:

• BlackRock, Inc.: 989,558 shares as of December 31, 2024, a change of 50,090 shares (5.332%).
• Praetorian PR LLC: 812,210 shares as of December 31, 2024, a change of 31,410 shares (4.023%).
• Vanguard Group Inc: 738,201 shares as of December 31, 2024, a change of 17,489 shares (2.427%).
• Raymond James Financial Inc: 475,551 shares as of December 31, 2024.
• Raymond James Financial Services Advisors, Inc.: 369,438 shares as of September 30, 2024, an increase of 141,904 shares (62.366%).
• Geode Capital Management, Llc: 363,602 shares as of December 31, 2024, a change of 19,136 shares (5.555%).
• Millennium Management Llc: 291,327 shares as of December 31, 2024, a change of 88,823 shares (43.862%).
• State Street Corp: 226,428 shares as of December 31, 2024 (0% change).
• Dauntless Investment Group, Llc: 191,822 shares as of December 31, 2024 (new position).

Institutional holdings account for approximately 31.11% of the company's stock. The total value of these holdings is about $52 million.

Recent trading activity shows mixed sentiment. INmune Bio Inc. (INMB) reported its Q4 2024 earnings, highlighting a focus on innovation in neuroinflammation and rare diseases. The stock closed at $7.73, down 4.14% during regular trading, but increased by 2.56% in aftermarket trading, reflecting mixed investor sentiment.

On April 17, 2025, the share price was $7.32, compared to $8.80 on April 18, 2024, representing a decline of 16.82% over that period. As of April 21, 2025, the market price was $7.28, with a day's range between $6.98 and $7.37.

Several analysts have provided coverage for INmune Bio, Inc. (INMB). Raymond James initiated coverage with an Outperform recommendation. The average one-year price target for INmune Bio, Inc. (INMB) is $23.87, with forecasts ranging from $20.20 to $31.50.

Based on 9 Wall Street analysts, 88% recommend a Buy rating, and 11% recommend a Hold rating. This suggests a generally positive outlook from analysts.

Recent insider trading activity shows that DAVID J MOSS (Chief Financial Officer) purchased 10,000 shares for an estimated $52,868.

Several institutional investors have increased their positions in INmune Bio, Inc. (INMB):

• RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. added 141,904 shares (+62.4%) in Q3 2024, for an estimated $764,862.
• UBS GROUP AG added 93,092 shares (+215.7%) in Q4 2024, for an estimated $434,739.
• MILLENNIUM MANAGEMENT LLC added 88,823 shares (+43.9%) in Q4 2024, for an estimated $414,803.
• PEKIN HARDY STRAUSS, INC. added 83,350 shares (+inf%) in Q4 2024, for an estimated $389,244.

However, some institutions have decreased their positions, such as CORTON CAPITAL INC., which removed 76,143 shares (-100.0%) in Q4 2024.

Short interest in INmune Bio, Inc. (INMB) is significant. As of March 31, 2025, the short interest was 6,060,191 shares, with an average share volume of 299,363.

The company's Q3 2024 results showed a net loss of approximately $12.1 million, compared to approximately $8.6 million during the same quarter in 2023. Research and development expenses totaled approximately $10.1 million, compared to $6.0 million in the previous year. As of September 30, 2024, the company had cash and cash equivalents of approximately $33.6 million.

Indian investors have shown increased interest in INmune Bio, Inc. (INMB), with search interest increasing by 167% in the last 30 days (March 9, 2025, to April 8, 2025).

Approximately 15.24% of the company's stock is owned by Institutional Investors, 17.01% is owned by Insiders, and 67.75% is owned by Public Companies and Individual Investors.

Top individual shareholders include:

• Raymond Joseph Tesi: 1,554,106 shares
• Mark William Lowdell: 1,510,806 shares
• David Moss: 1,285,869 shares

For further insights into INmune Bio, Inc. (INMB)'s financial health, consider exploring: Breaking Down INmune Bio, Inc. (INMB) Financial Health: Key Insights for Investors